Complication rates of 16- and 18-gauge needles for native kidney biopsies: a systematic review and proportional meta-analysis.

Ren FailMay 25, 2026 (epub)
Clinical ResearchNephrologyOpen access

Marie Møller, Tue H Andersen, Rikke Borg et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed complication rates and diagnostic yield of 16-gauge (16G) versus 18-gauge (18G) needles in adult native kidney biopsies. Analyzing 62 studies with 22,208 biopsies, the pooled major complication rates were 1.83% for 16G and 1.29% for 18G, showing no statistically significant difference. The study highlights the need for direct comparative trials.

Key findings

  • Pooled major complication rate for 16G needles was 1.83% (95% CI: 1.20-2.79).
  • Pooled major complication rate for 18G needles was 1.29% (95% CI: 0.78-2.13).
  • Mean glomerular yield was 18.8 for 16G and 17.5 for 18G needles.
  • Higher prevalence of acute kidney injury correlated with increased complication rates.

Why it matters

Understanding the safety profiles of different needle sizes in kidney biopsies is crucial for clinicians to minimize complications while ensuring adequate diagnostic yield. This evidence can inform clinical decision-making regarding needle selection.

Source

PubMed · PMID 42185739Free full text on PubMed Central

Published in Ren Fail. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.